179 related articles for article (PubMed ID: 32709714)
1. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
Ahmed FS; Gaule P; McGuire J; Patel K; Blenman K; Pusztai L; Rimm DL
Clin Cancer Res; 2020 Oct; 26(20):5456-5461. PubMed ID: 32709714
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed immunofluorescence identifies high stromal CD68
Wang J; Browne L; Slapetova I; Shang F; Lee K; Lynch J; Beretov J; Whan R; Graham PH; Millar EKA
Sci Rep; 2021 Nov; 11(1):21608. PubMed ID: 34732817
[TBL] [Abstract][Full Text] [Related]
3. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Dirix LY; Takacs I; Jerusalem G; Nikolinakos P; Arkenau HT; Forero-Torres A; Boccia R; Lippman ME; Somer R; Smakal M; Emens LA; Hrinczenko B; Edenfield W; Gurtler J; von Heydebreck A; Grote HJ; Chin K; Hamilton EP
Breast Cancer Res Treat; 2018 Feb; 167(3):671-686. PubMed ID: 29063313
[TBL] [Abstract][Full Text] [Related]
4. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
[TBL] [Abstract][Full Text] [Related]
5. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Quintela-Fandino M; Holgado E; Manso L; Morales S; Bermejo B; Colomer R; Apala JV; Blanco R; Muñoz M; Caleiras E; Iranzo V; Martinez M; Dominguez O; Hornedo J; Gonzalez-Cortijo L; Cortes J; Gasol Cudos A; Malon D; Lopez-Alonso A; Moreno-Ortíz MC; Mouron S; Mañes S
Breast Cancer Res; 2020 Nov; 22(1):124. PubMed ID: 33176887
[TBL] [Abstract][Full Text] [Related]
6. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
O'Rourke H; Hart C; De Boer RH
Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
[TBL] [Abstract][Full Text] [Related]
7. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
Wood SJ; Gao Y; Lee JH; Chen J; Wang Q; Meisel JL; Li X
Breast Cancer Res Treat; 2024 May; 205(1):193-199. PubMed ID: 38286889
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer.
Antony GR; Littleflower AB; Parambil ST; Subhadradevi L
Med Oncol; 2023 Feb; 40(4):108. PubMed ID: 36842157
[TBL] [Abstract][Full Text] [Related]
9. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis.
Wei Y; Wu Y; Luo Y; Ma F
Crit Rev Oncol Hematol; 2024 Apr; 196():104309. PubMed ID: 38423376
[TBL] [Abstract][Full Text] [Related]
11. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.
Arqueros C; Gallardo A; Vidal S; Osuna-Gómez R; Tibau A; Lidia Bell O; Ramón Y Cajal T; Lerma E; Lobato-Delgado B; Salazar J; Barnadas A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473874
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-responsive spherical nucleic acid against c-Myc/PD-L1 to enhance anti-tumoral macrophages in triple-negative breast cancer progression.
Wang R; Li G; Gao F; Xu F; Li X; Zhang J; Li J; Guan X
Sci China Life Sci; 2024 Apr; 67(4):698-710. PubMed ID: 38151609
[TBL] [Abstract][Full Text] [Related]
13. Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
Kim SM; Park N; Park HB; Lee J; Chun C; Kim KH; Choi JS; Kim HJ; Choi S; Lee JH
PLoS One; 2024; 19(5):e0303433. PubMed ID: 38743676
[TBL] [Abstract][Full Text] [Related]
14. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
Kato S; Okamura R; Kumaki Y; Ikeda S; Nikanjam M; Eskander R; Goodman A; Lee S; Glenn ST; Dressman D; Papanicolau-Sengos A; Lenzo FL; Morrison C; Kurzrock R
Oncoimmunology; 2020; 9(1):1708065. PubMed ID: 32117584
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J; Silber A; Reisenbichler E; Singh K; Fischbach N; Persico J; Adelson K; Katoch A; Horowitz N; Lannin D; Chagpar A; Park T; Marczyk M; Frederick C; Burrello T; Ibrahim E; Qing T; Bai Y; Blenman K; Rimm DL; Pusztai L
NPJ Breast Cancer; 2021 Feb; 7(1):9. PubMed ID: 33558513
[TBL] [Abstract][Full Text] [Related]
16. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.
Li Y; Yue L; Zhang S; Wang X; Zhu YN; Liu J; Ren H; Jiang W; Wang J; Zhang Z; Liu T
Comput Biol Med; 2024 Jun; 176():108537. PubMed ID: 38744008
[TBL] [Abstract][Full Text] [Related]
17. Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.
Izadi S; Gumpelmair S; Coelho P; Duarte HO; Gomes J; Leitner J; Kunnummel V; Mach L; Reis CA; Steinberger P; Castilho A
Plant Biotechnol J; 2024 May; 22(5):1224-1237. PubMed ID: 38050338
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Fountzila E; Ignatiadis M
Ecancermedicalscience; 2020; 14():1147. PubMed ID: 33574892
[TBL] [Abstract][Full Text] [Related]
19. Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.
Seager RJ; Ko H; Pabla S; Senosain MF; Kalinski P; Van Roey E; Gao S; Strickland KC; Previs RA; Nesline MK; Hastings S; Zhang S; Conroy JM; Jensen TJ; Eisenberg M; Caveney B; Severson EA; Ramkissoon S; Gandhi S
J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793063
[No Abstract] [Full Text] [Related]
20. Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Donati B; Reggiani F; Torricelli F; Santandrea G; Rossi T; Bisagni A; Gasparini E; Neri A; Cortesi L; Ferrari G; Bisagni G; Ragazzi M; Ciarrocchi A
Cancer Immunol Res; 2024 Jan; 12(1):120-134. PubMed ID: 37856875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
